Results 101 to 110 of about 734,043 (307)

Pharmacogenetics of analgesic drugs [PDF]

, 2013
• Individual variability in pain perception and differences in the efficacy of analgesic drugs are complex phenomena and are partly genetically predetermined.
Branford, R, Cregg, R, Gubbay, A, Russo, G, Sato, H   +4 more
core   +1 more source

ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma

Molecular Oncology, EarlyView.
In SMAD4‐positive pancreatic ductal adenocarcinoma (PDAC), integrin subunit alpha V (ITGAV) activates latent TGF‐β, which binds to the TGF‐β receptor and phosphorylates SMAD2/3. The activated SMAD2/3 forms a complex with SMAD4, and together they translocate to the nucleus, modulating gene expression to promote proliferation, migration, and invasion. In
Daniel K. C. Lee, Keyue Chen, Ryan Loke, Xiang Li, David Liubart, Golam T. Saffi, Jonathan T. S. Chow, Ché M. P. Melo, Lydia To, Leonardo Salmena   +9 more
wiley   +1 more source

The 90% minimum effective volume and concentration of lidocaine for ultrasound-guided stellate ganglion blocks in adults: a biased-coin design, up-and-down sequential allocation trial [PDF]

Korean Journal of Anesthesiology
Background As ultrasound imaging technology matured, stellate ganglion blocks (SGBs) have become increasingly precise and safe, and their use in clinical practice has become widespread. However, the 90% minimum effective volume (MEV90) and concentration (
Shujun Sun, Qinghua Yin, Jiwei Shen, Yang Lv, Long Li, Zhangyan Mao, Yun Lin, Xiangdong Chen, Dong Yang   +8 more
doaj   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Supplementary table 2 from Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

, 2023
<p>Supplementary table 2. Multivariate model for overall survival (Molecularly Targeted Agents).</p>
Stan B. Kaye, Jaap Verweij, Josep Tabernero, Jean Charles Soria, Richard H. Wilson, Ruth Plummer, Jeffrey Evans, Emile Voest, Nicolas Penel, Jan H.M. Schellens, Silvia Marsoni, Patrick Schöffski, Andre T. Brunetto, Elisa Gallerani, Gianluca Del Conte, Rafael Morales-Barrera, Philippe A. Cassier, Carlos Gomez-Roca, David Olmos, Victor Moreno García   +19 more
openaire   +1 more source

Hallucinogens: mechanisms and medical complications [PDF]

, 2013
Thesis (M.A.)--Boston UniversityHallucinogens are drugs that alter consciousness by distorting primarily auditory and visual perception but they can affect any sensory system. Hallucinogens also affect judgment, orientation, memory, or emotion.
Chan, Ryan Harry Alexander
core   +1 more source

Amphetamine, but not methylphenidate, increases ethanol intake in adolescent male, but not in female, rats [PDF]

, 2018
Introduction: There has been an increasing interest in analyzing the interactions between stimulants and ethanol during childhood and adolescence. Stimulants are used to treat attention-deficit hyperactivity disorder (ADHD) in these developmental stages,
Acevedo, Adriani, Aleksandrov, Andersen, Atianjoh, Berardo, Brandon, Brunelle, Burke, Camarini, Chong, Crawford, Crowley, Cryan, Dalsgaard, Diaz Heijtz, Doremus-Fitzwater, Duke, Fahlke, Feltmann, Fernandez, Frey, Frolov, Gaytan, Gaytan, Gaytan, Gaytan, Gill, Gowin, Heinz, Izenwasser, Jones, Justo, Kameda, Karanikas, Karim, Kozanian, Krasnova, Kuczenski, Kuczenski, Lambert, Mandt, Mannuzza, McClintick, McCullough, McDougall, McDougall, Naimi, National-Research-Council, Pascual, Pilatti, Pilatti, Pilatti, Pinsky, Ponce, Quinn, Quinn, Renard, Ruiz, Salisbury, Schenk, Schuckit, Schuckit, Soeters, Spear, Spear, Sripada, Stewart, Strakowski, Tirelli, Vendruscolo, Venkataraman, Venniro, Wagner, Wetzell, Wille-Bille, Winer, Wolgin   +77 more
core   +1 more source

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

Population pharmacokinetics [PDF]

Vojnosanitetski Pregled, 2005
Milovanović Jasmina R., Janković Slobodan M.   +1 more
doaj   +1 more source

Supplementary table 3 from Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

, 2023
<p>Supplementary table 3. Multivariate model for Overall Survival (Cytotoxic Agents)</p>
Stan B. Kaye, Jaap Verweij, Josep Tabernero, Jean Charles Soria, Richard H. Wilson, Ruth Plummer, Jeffrey Evans, Emile Voest, Nicolas Penel, Jan H.M. Schellens, Silvia Marsoni, Patrick Schöffski, Andre T. Brunetto, Elisa Gallerani, Gianluca Del Conte, Rafael Morales-Barrera, Philippe A. Cassier, Carlos Gomez-Roca, David Olmos, Victor Moreno García   +19 more
openaire   +1 more source